Shanghai Allist Pharmaceuticals Co. Ltd. A
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China. Its lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC), as well as for treating adult patients with locally advanced or metastatic NSCLC. The co… Read more
Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) - Total Assets
Latest total assets as of September 2025: CN¥7.26 Billion CNY
Based on the latest financial reports, Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) holds total assets worth CN¥7.26 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai Allist Pharmaceuticals Co. Ltd. A - Total Assets Trend (2017–2024)
This chart illustrates how Shanghai Allist Pharmaceuticals Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shanghai Allist Pharmaceuticals Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Allist Pharmaceuticals Co. Ltd. A's total assets of CN¥7.26 Billion consist of 70.7% current assets and 29.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.9% |
| Accounts Receivable | CN¥394.21 Million | 6.7% |
| Inventory | CN¥30.56 Million | 0.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥232.42 Million | 3.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Shanghai Allist Pharmaceuticals Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Allist Pharmaceuticals Co. Ltd. A's current assets represent 70.7% of total assets in 2024, a decrease from 79.6% in 2017.
- Cash Position: Cash and equivalents constituted 9.9% of total assets in 2024, down from 11.6% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 6.7% of total assets.
Shanghai Allist Pharmaceuticals Co. Ltd. A Competitors by Total Assets
Key competitors of Shanghai Allist Pharmaceuticals Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Shanghai Allist Pharmaceuticals Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Shanghai Allist Pharmaceuticals Co. Ltd. A generates 0.60x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Shanghai Allist Pharmaceuticals Co. Ltd. A generates $ 24.17 in net profit.
Shanghai Allist Pharmaceuticals Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.39 | 6.96 | 24.58 |
| Quick Ratio | 5.34 | 6.89 | 24.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.25 Billion | CN¥ 3.25 Billion | CN¥ 2.57 Billion |
Shanghai Allist Pharmaceuticals Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Shanghai Allist Pharmaceuticals Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.98 |
| Latest Market Cap to Assets Ratio | 0.49 |
| Asset Growth Rate (YoY) | 35.2% |
| Total Assets | CN¥5.92 Billion |
| Market Capitalization | $2.90 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Allist Pharmaceuticals Co. Ltd. A's assets below their book value (0.49 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Shanghai Allist Pharmaceuticals Co. Ltd. A's assets grew by 35.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Shanghai Allist Pharmaceuticals Co. Ltd. A (2017–2024)
The table below shows the annual total assets of Shanghai Allist Pharmaceuticals Co. Ltd. A from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.92 Billion | +35.18% |
| 2023-12-31 | CN¥4.38 Billion | +27.14% |
| 2022-12-31 | CN¥3.44 Billion | +9.96% |
| 2021-12-31 | CN¥3.13 Billion | +4.79% |
| 2020-12-31 | CN¥2.99 Billion | +124.86% |
| 2019-12-31 | CN¥1.33 Billion | +254.25% |
| 2018-12-31 | CN¥375.00 Million | -26.27% |
| 2017-12-31 | CN¥508.63 Million | -- |